• Pyxis Oncology highlighted MICVO, an extracellular-targeting antibody-drug conjugate in clinical development that targets EDB+FN in tumor extracellular matrix.
• Phase 1 dose escalation dosed 80 patients across 18 sites, exploring 0.3-8.0 mg/kg Q3W, with dose-dependent responses starting at 3.6 mg/kg.
• In R/M HNSCC, responses were reported at 3.6 mg/kg and 5.4 mg/kg; confirmed ORR was 50% with 100% disease control rate.
• 5.4 mg/kg was selected for dose expansion based on benefit-risk; monotherapy received FDA Fast Track designation.
• Multiple clinical data catalysts were flagged for 2H 2026, including monotherapy dose expansion in 2L+ R/M HNSCC and MICVO with KEYTRUDA dose escalation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pyxis Oncology Inc. published the original content used to generate this news brief on June 30, 2026, and is solely responsible for the information contained therein.